Positron Emission Tomography in Neurological Diseases

Positron Emission Tomography in Neurological Diseases

Abstract

  • Positron Emission Tomography (PET) is a non-invasive imaging technology that studies human physiology.
  • PET uses positron-emitting radiopharmaceuticals to measure metabolic and functional activity of living tissues.
  • The focus of this review is on the application of PET in neurology, analyzing its relevance in conditions such as epilepsy, stroke, dementia, and movement disorders.
  • PET is not recommended as a primary imaging technique but is useful in specific cases, particularly when combined with CT or MRI.
  • Limitations include availability and high costs, emphasizing the need for judicious patient selection for PET scans.

Overview of PET Procedure

  • Basic steps for PET imaging include:
    1. Fasting: 4-hour fasting (relaxed for diabetics).
    2. Tracer Administration: Administer 10 mCi of FDG (Fluorodeoxyglucose) via IV after a 5-min relaxation in a dimly lit room.
    3. Rest: Patient rests for 40 min post-injection in a similar environment.
    4. Imaging: Imaging conducted 40 min after injection and lasts 15 min.
    • Dose of radionuclide is minimal and presents no significant hazard.
    • Various isotopes can be used depending on the region and function studied.

Clinical Applications of PET

1. Oncology
  • Differentiation of Tumors: Distinguishes malignant from benign tumors.
  • Biopsy Guidance: Locates optimal biopsy sites for suspected tumors.
  • Therapy Monitoring: Monitors effects of radiation or chemotherapy and detects recurrent disease.
  • Early Detection: Detects cancers such as those of the breast, colon, and lung at early stages where traditional imaging fails.
2. Cardiology
  • Disease Assessment: Evaluates the extent of cardiovascular disease, particularly coronary artery disease.
  • Identify Viable Myocardium: Assists in determining candidates for revascularization procedures (stenting or bypass surgery).
3. Neurology
A. Epilepsy
  • Diagnosis: Presurgical evaluation to localize epileptogenic foci; interictal PET shows decreased glucose metabolism and blood flow.
    • Comparison of imaging techniques indicates!
      • MR Imaging: 60% localization rate.
      • Ictal SPECT: 70% localization rate.
      • Interictal 18F-2-deoxyglucose (18FDG) PET: 78% localization rate.
  • Invasive Procedure Avoidance: Often negates the need for invasive monitoring, although combining PET with invasive techniques provides higher localization precision.
  • Temporal Lobe Epilepsy (TLE): [11C]deuterium-deprenyl PET aids in identifying epileptogenic temporal lobes. Seizure lateralization shows qualitative simplicity with PET over MR.
B. Stroke
  • Cortical Infarction Prediction: Comparison of [11C]flumazenil-PET and diffusion-weighted MRI reveals comparable predictions for cortical infarction, with FMZ-PET showing lower false-positive rates.
  • Identification of Viable Penumbra: PET differentiates irreversibly damaged tissue from viable penumbra, crucial for successful reperfusion.
  • Differentiation of Stroke Types: Cobalt-55 PET used to differentiate between recent (<2 months) and old strokes (6 months to 1 year).
  • Neuronal Implantation Prediction: PET with 18F-FDG correlates metabolic brain response in neuronal cell implantation trials for stroke.
C. Dementia
  • Detection of Progressive Dementia: 18FDG-PET shows sensitivity of 93% and specificity of 76% in cognitive impairment evaluations, with enhanced sensitivity in Alzheimer's Disease (AD) patients.
  • Differential Diagnosis: PET can differentiate AD from vascular dementia, showing unique metabolic patterns.
  • Monitoring Treatment Effects: Evaluates treatment benefits for Alzheimer's based on cholinesterase inhibitors.
  • Preclinical Diagnosis: Useful in early diagnosis, showing AD-associated abnormalities detectable before clinical symptoms appear.
D. Movement Disorders

  1. Parkinson's Disease (PD):

    • Diagnosis in Early Stages: 18Fluorodopa-PET quantifies dopamine synthesis defects indicating early PD.
    • Distinguishing Movement Disorders: PET helps differentiate PD from essential tremors and striatonigral degeneration (SND).
    • Progression Monitoring: Evaluates disease progression and treatment efficacy.

  2. Huntington's Disease (HD):

    • Preclinical Detection: Reduced caudate glucose utilization in high-risk individuals detected through PET aiding confirmation of DNA study results.

  3. Brain Tumors:

    • Differentiation of Tumor Types: PET aids in distinguishing between malignant and benign tumors and differentiates recurrence from radiation necrosis.
    • Tumor Grading: 2-[18F]-fluoroethyl-l-tyrosine (FET) PET can evaluate tumor grade.
4. Miscellaneous Applications
  • Headaches: Increased blood flow observed in migraine patients during headache phases via PET potential diagnostic use.
  • Chronic Fatigue Syndrome: FDG-PET suggests hypometabolism in specific brain regions.
  • Encephalitis: Shows diffuse unilateral hypometabolism in Rasmussen's encephalitis, enhancing diagnostic confidence.

Limitations of PET

  • Availability: Limited mostly to developed countries and larger research institutes. In India, PET is primarily available only at select hospitals.
  • Costs: High costs (approximately INR 25,000 or 555 USD), hindering accessibility.
  • False Positives: Relatively high rate of false positives affects specificity.
  • Technical Requirements: High qualification criteria for personnel interpreting PET scans, alongside cyclotrons for isotope generation.

Conclusion

  • Utility of PET: PET is a valuable neuroimaging tool with significant implications for diagnosing, treating, and monitoring neurological disorders.
  • Role Definition Needed: While it plays a critical role in epilepsy localization and stroke assessment, PET’s broader applications require further validation and research.